

## PRIOR AUTHORIZATION POLICY

- POLICY:** Lucemyra Prior Authorization Policy
- Lucemyra™ (lofexidine tablets – US WorldMeds)

**REVIEW DATE:** 07/21/2021

---

### OVERVIEW

Lucemyra, a central alpha-2 adrenergic agonist, is indicated for **mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation** in adults.<sup>1</sup>

Lucemyra is typically dosed four times daily during the period of peak withdrawal symptoms (generally the first 5 to 7 days following last use of opioid) with dosing guided by symptoms and adverse events.<sup>1</sup> Lucemyra treatment may continue for up to 14 days with dosing guided by symptoms. Discontinue Lucemyra with a gradual dose reduction over a 2- to 4-day period to mitigate Lucemyra withdrawal symptoms.

### Disease Overview

Opioid addiction (or opioid use disorder) is a primary, chronic and relapsing central nervous system (CNS) disease of brain reward, motivation, memory, and related circuitry characterized by an individual pathologically pursuing reward and/or relief by substance use and other behaviors.<sup>4</sup> Since the 1990s, opioid use and abuse have risen markedly in the US.<sup>5</sup> Symptoms of opioid withdrawal usually begin two to three half-lives after the last opioid dose (6 to 12 hours for short half-life opioids such as heroin and morphine and 36 to 48 hours for long half-life opioids such as methadone).<sup>6</sup> Following cessation of a short half-life opioid, symptoms reach peak intensity within 2 to 4 days, with most of the physical withdrawal signs no longer apparent after 7 to 14 days. The duration of withdrawal also varies with the half-life of the opioid used and the duration of use. While opioid withdrawal is rarely life-threatening, the combination of uncomfortable symptoms and intense craving makes completion of withdrawal difficult for most people.

### Guidelines

The American Psychiatric Association (APA) practice guideline for the treatment of patients with substance use disorders (2006) notes several strategies as effective treatments for opioid dependence including the abrupt discontinuation of the opioid with the use of clonidine to suppress withdrawal symptoms and clonidine-naltrexone detoxification, where withdrawal symptoms are precipitated by naltrexone and then suppressed by clonidine.<sup>2</sup> Clonidine reduces withdrawal symptoms such as nausea, vomiting, diarrhea, cramps, and sweating.<sup>2,3</sup> The guidelines note that the completion rate for clonidine-treated outpatients is relatively low and roughly comparable to that of methadone withdrawal.

The American Society of Addiction Medicine (ASAM) practice guideline for the treatment of opioid use disorder (2020) discusses two primary strategies for the management of opioid withdrawal.<sup>3</sup> In one strategy, alpha-2 adrenergic agonists (i.e., clonidine, Lucemyra) are used along with other non-narcotic medications to reduce withdrawal symptoms. The use of non-opioid medications may be the only option available in some healthcare settings and may also assist the transition of patients to opioid antagonist medications (i.e., naltrexone) helping to prevent subsequent relapse. Comparative data are limited but Lucemyra and clonidine appear to be similarly effective in the treatment of opioid withdrawal with hypotension occurring less frequently with Lucemyra. While clonidine is not FDA-approved for the treatment of opioid withdrawal, it has been extensively used off-label for this purpose. Clonidine can be combined with other non-narcotic medications targeting specific opioid withdrawal symptoms. ASAM

states that alpha-2 adrenergic agonists are safe and effective for management of opioid withdrawal. However, the guideline notes that methadone and buprenorphine are more effective in reducing the symptoms of opioid withdrawal, in retaining patients in withdrawal management, and in supporting the completion of withdrawal management.

### **POLICY STATEMENT**

Prior Authorization is recommended for prescription benefit coverage of Lucemyra. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Lucemyra as well as the monitoring required for adverse events, initial approval requires Lucemyra to be prescribed by or in consultation with a physician who specializes in the condition being treated.

**Automation:** None.

### **RECOMMENDED AUTHORIZATION CRITERIA**

Coverage of Lucemyra is recommended in those who meet the following criteria:

#### **FDA-Approved Indications**

- 1. Opioid Withdrawal Symptoms.** Approve for 2 weeks (14 days) if the patient meets the following criteria (A and B):
  - A)** Lucemyra is being used to facilitate abrupt opioid discontinuation; **AND**
  - B)** Patient has a history of clonidine use (e.g., patches, tablets) and experienced unacceptable toxicity and/or inadequate efficacy.

### **CONDITIONS NOT RECOMMENDED FOR APPROVAL**

Coverage of Lucemyra is not recommended in the following situations:

- 1. Cannabis Use Disorder (Cannabis Dependence).** One published study has evaluated the safety and efficacy of dronabinol and lofexidine in treating cannabis dependence (n = 156).<sup>7</sup> In this 11-week, placebo-controlled study, the combined intervention did not show efficacy as a treatment for cannabis use disorder.
- 2.** Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

### **REFERENCES**

1. Lucemyra™ tablets [prescribing information]. Louisville, KY: US WorldMeds, LLC; May 2018.
2. Kleber HD, Weiss RD, Anton Jr., RF, et al. American Psychiatric Association practice guideline for the treatment of patients with substance use disorders, second edition. *Am J Psychiatry*. 2007;164(Suppl 4):5-123. Available at: <https://psychiatryonline.org/guidelines>. Accessed on July 20, 2021.
3. Cunningham C, Edlund MJ, Fishman M, et al. The American Society of Addiction Medicine National Practice Guideline for the treatment of opioid use disorder. 2020 Focused Update. Available at: <https://www.asam.org/Quality-Science/quality/2020-national-practice-guideline>. Accessed on July 20, 2021.
4. American Society of Addiction Medicine. Opioid addiction 2016 facts & figures. Available at: <http://www.asam.org/docs/default-source/advocacy/opioid-addiction-disease-facts-figures.pdf>. Accessed on July 20, 2021.
5. Dixon DW, Peirson RP. Opioid abuse. Page last updated: March 23, 2020. Available at: <http://emedicine.medscape.com/article/287790-overview#showall>. Accessed on July 20, 2021.

6. Gowing L, Farrell M, Ali R, et al. Alpha2-adrenergic agonists for the management of opioid withdrawal (Review). *Cochrane Database Syst Rev.* 2016;5:CD002024.
7. Levin FR, Marjani JJ, Pavlicova M, et al. Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial. *Drug Alcohol Depend.* 2016;159:53-60.